Uitgelichte items
Centrient Pharmaceuticals to acquire Astral SteriTech, expanding its product portfolio with sterile injectable antibiotic finished dosage forms
Centrient Pharmaceuticals, the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited, a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position as the global business-to-business industry leader in beta-lactam antibiotics.
read moreHere's why we think you should come work with us:
- Make an impact
- Build a winning career
- Become part of a global network
2200
employees around the globe
150
years of innovation
75
years of antibiotics
14
locations
Close to customers everywhere
Our manufacturing sites and sales offices around the globe are the cornerstones of our customer and supplier relationships, providing on-the-ground support and ensuring security of supply
